about
The potential impact of pneumococcal conjugate vaccine in Africa: Considerations and early lessons learned from the South African experiencePorcine Rotaviruses: Epidemiology, Immune Responses and Control Strategies.Monovalent Rotavirus Vaccine Effectiveness and Impact on Rotavirus Hospitalizations in Zanzibar, Tanzania: Data From the First 3 Years After Introduction.Investigation of Stilbenoids as Potential Therapeutic Agents for Rotavirus Gastroenteritis.A significant and consistent reduction in rotavirus gastroenteritis hospitalization of children under 5 years of age, following the introduction of universal rotavirus immunization in IsraelUse of Internet Search Data to Monitor Rotavirus Vaccine Impact in the United States, United Kingdom, and Mexico.Effectiveness of Rotavirus Vaccination: A systematic review of the first decade of global post-licensure data, 2006-2016.Did Large-Scale Vaccination Drive Changes in the Circulating Rotavirus Population in Belgium?Safety and Immunogenicity of Sequential Rotavirus Vaccine Schedules.Diversity in Rotavirus-Host Glycan Interactions: A "Sweet" Spectrum.Rotavirus vaccination and intussusception - Science, surveillance, and safety: A review of evidence and recommendations for future research priorities in low and middle income countries.Reassortment in segmented RNA viruses: mechanisms and outcomes.Current status of rotavirus vaccines.Estimated reductions in hospitalizations and deaths from childhood diarrhea following implementation of rotavirus vaccination in Africa.Rotavirus vaccines: current global impact and future perspectives.The Need for an Information Communication and Advocacy Strategy to Guide a Research Agenda to Address Burden of Invasive Nontyphoidal Salmonella Infections in Africa.Dietary Human Milk Oligosaccharides but Not Prebiotic Oligosaccharides Increase Circulating Natural Killer Cell and Mesenteric Lymph Node Memory T Cell Populations in Noninfected and Rotavirus-Infected Neonatal Piglets.Safety and immunogenicity of a live attenuated pentavalent rotavirus vaccine in HIV-exposed infants with or without HIV infection in Africa.Epidemiology of group A rotavirus infection after the introduction of monovalent vaccine in the National Immunization Program of Saudi Arabia.Potential safety issues and other factors that may affect the introduction and uptake of rotavirus vaccines.Impact and Effectiveness of Monovalent Rotavirus Vaccine in Armenian Children.Sustained Reduction of Childhood Diarrhea-Related Mortality and Hospitalizations in Mexico After Rotavirus Vaccine Universalization.Rotavirus strain surveillance for three years following the introduction of rotavirus vaccine into Belém, Brazil.2017 Infectious Diseases Society of America Clinical Practice Guidelines for the Diagnosis and Management of Infectious Diarrhea.Rotavirus infection.Decreased performance of live attenuated, oral rotavirus vaccines in low-income settings: causes and contributing factors.Intussusception Rate Aamong Uunder-Five-Children Before Introduction of Rotavirus Vaccine in North India.Annual changes in rotavirus hospitalization rates before and after rotavirus vaccine implementation in the United States.Effect of Age at Vaccination on Rotavirus Vaccine Effectiveness in Bolivian Infants.Can Changes to Scheduling Enhance the Performance of Rotavirus Vaccines in Low-Income Countries?
P2860
Q28088507-B3DCA7CF-4334-442B-A2DD-756F4BCB0CE3Q30235130-8B22A468-CD1F-4200-BF89-FD4F683A5B97Q31141017-7BA74138-00BB-4636-9273-D9596D35E591Q36038473-5AAC9DD2-08F9-474C-B092-EAB58DE9D565Q36256433-8F89F5BE-F641-4BFA-8F50-2337D361A71FQ36332199-3A023885-6B93-460C-964D-17638CB709E9Q36356363-1B97805F-8232-4046-8682-AE86710F714EQ36388856-B3A8DB8C-673A-47F0-AB2E-2039497A7586Q36518775-40A07F38-8FF7-4197-84F9-8048EB90E90AQ37296744-748511BF-92BB-4BA7-BF49-AEEF0347CA8EQ37375904-FCA806B4-F55F-441D-8B5A-3531CFED3A3EQ37428960-F67F5DF7-635F-4C84-9EF4-E08B87BB8853Q38603768-C19FF403-DE60-4ADB-807C-16C37EBFC10CQ38612845-6330CCF3-6D73-4AE6-90B3-5C748EAD8F62Q38795738-7B648DB6-E99E-4D42-BB9D-ACCB467B547FQ39093995-991CB2EC-5BC2-497A-B9D2-4AEA3F75C1C3Q40206940-BBCA1834-BD18-4853-B3C2-4356F40A551BQ40529372-CE278BDA-CE50-4287-A5AF-BA5546FCCAAAQ40573143-3359D3F6-D4D2-4A2B-A7DF-FE8DD3B7C341Q40693674-A773E89D-9815-4D54-8F6F-8BD544970F1FQ40722626-E1834014-EA05-4BBD-8CED-8F7CA2D92A51Q40722641-9C356EFA-A092-44DF-8C84-74A08F056D50Q41329103-992715BB-AAED-4CF6-9534-82915A3EDCACQ45070596-2BFCE12B-1EAF-45CF-BC0A-2C008B0C0EB6Q46152582-90E58B69-5836-4795-93BD-BF5D662D0846Q47291480-B66D75EE-FE37-4ECF-B9D1-6EDA11513352Q47776036-9C82B23F-2B1C-4787-9DD2-06A6C9940074Q50000537-DAAA7BDD-D239-4341-AD28-8A899BC74F2EQ50002778-3A0BEB03-B5BE-42D2-B542-97AC01D598CAQ54674897-AF688DBF-86B7-4A33-B080-67B8B31D7F65
P2860
description
2014 nî lūn-bûn
@nan
2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Rotavirus vaccines in routine use
@ast
Rotavirus vaccines in routine use
@en
Rotavirus vaccines in routine use
@nl
type
label
Rotavirus vaccines in routine use
@ast
Rotavirus vaccines in routine use
@en
Rotavirus vaccines in routine use
@nl
prefLabel
Rotavirus vaccines in routine use
@ast
Rotavirus vaccines in routine use
@en
Rotavirus vaccines in routine use
@nl
P2860
P3181
P356
P1476
Rotavirus vaccines in routine use
@en
P2093
J. E. Tate
U. D. Parashar
P2860
P304
P3181
P356
10.1093/CID/CIU564
P407
P577
2014-11-01T00:00:00Z